PeptideTherapeutics in Metabolic Disorders Market, By Route of Administration(Intravenous, Oral, Nasal, and Others), By Synthesis Technology (Solid PhasePeptide Synthesis, Liquid Phase Peptide Synthesis, and Hybrid Technology), andBy Distribution Channels (Hospitals, Specialty Clinics, Retail Pharmacy, andOnline Pharmacy) - Size, Share, Outlook, and Opportunity Analysis, 2017–2025
Peptide therapeutics, due totheir various advantages such as high stability, selectivity, safety, efficacy,bioavailability, and tolerability offers wide applications over the othertherapeutics classes. Over 7,000 naturally occurring peptides have beenidentified, which have crucial roles in human physiology, which includehormones, neurotransmitters, growth factors, ion channel, and ligands. Thestructure of these peptides is usually complex and these conformationsdepending upon their environment.
Manufacturers are focusing ondevelopments in biologics and biopharmaceutical peptides and proteins forapplication in diagnostics and therapies. According to the data published inDrug Discovery Today, in January 2015, around 140 peptide therapeutics arecurrently evaluated in clinical trials. Peptide therapeutics are increasinglybeen used for therapeutics in metabolic diseases and oncology. Rising incidenceof metabolic diseases such as Diabetes mellitus type 2 (T2DM) and Obesity areexpected to be factors driving growth of the market. According to World HealthOrganization (WHO) 2017 data findings, the number people suffering fromdiabetes have increased from 108 million to 422 million in 2014. Similarly, theworld obesity rate has increased three times since 1975 and in 2016, over 1.9billion adults (18 year and above) were estimated to be overweight.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2003
Moreover, high incidence rate ofmetabolic disorders is expected to propel growth of peptide therapeutics inmetabolic disorders market in the near future. According to the Centers forDisease Control and Prevention (CDC) October 2017 data findings, in 2011–2012,78 million U.S. adults had low-density lipoprotein cholesterol levels, whichput them at high risk of heart disease and stroke. However, high prices ofproducts is expected to negatively impact the overall market growth.
Among the metabolic disorders,the risk of developing type 1 and type 2 diabetes is related to the combinationof variants in multiple genes. In rare cases, patients which are monogenichaving single gene mutation which can lead to diabetes. The first peptide to beadministrated therapeutically was insulin and has been used in the treatment ofdiabetes. Development of novel analogues such as lispro insulin that is aninjection to be taken prior to meal, has also aided in growth of the market.Another important peptide is glucagon like peptide-1 (GLP-1), which hasinsulin-releasing properties and also helps to suppress the glucagon level. Theglucose dependent action of GLP-1 is more potent to regulate glucose levelafter a meal. These properties of peptides has aided in development of noveltherapeutics and is expected to drive growth of the market in the near future.According to the data published in the January 2015, in Drug Discovery TodayJournal, total 60 peptides-based drugs such as viscozyme, pulmozyme, glucagenare available in the market and number of other therapeutic peptides such ascpd86 (preclinical), MOD-6030 (preclinical), MAR709 (II) and semaglutide (III)are currently evaluated in different phase of clinical trial thus, strongpipeline is expected to propel growth of the peptide therapeutics in metabolicdisorders market in the near future.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/peptide-therapeutics-in-metabolic-disorders-market-2003
Collaborations and new productlaunches:
Key players in the market arefocusing on collaborations and new product launches, in order to enhance theirmarket share. For instance, Rhythm Pharmaceuticals Inc. is engaged indeveloping obesity drug called setmelanotide a Melanocortin 4 receptor (MC4R)agonist peptide that is meant to be injected daily to regulate the body energybalance and appetite. Moreover, in June 2017, Rhythm Pharmaceuticals andCamurus AB released the positive initial results from ongoing Phase 1A clinicaltrial, which evaluated the pharmacokinetics and tolerability of anextended-release formulation of setmelanotide. The company is also conductingtrials for the treatment of extremely rare metabolic disorders such asPro-opiomelanocortin (POMC) and Leptin receptor (LepR) deficiency obesity.Furthermore, in September, 2017, Zealand Pharma and Torrey Pines Institute forMolecular Studies entered into a research collaboration for multi-targetresearch to identify novel peptide-based products by using Torrey PinesInstitute for Molecular Studies (TPIMS’s) peptide libraries. This collaborationwill help to develop specialty medicines to treat metabolic andgastrointestinal diseases.
Key players in the PeptideTherapeutics in Metabolic Disorders Market:
Some of the key players operatingin the market are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., TevaPharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company,Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, RhythmPharmaceuticals Inc., and Novo Nordisk A/S.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2003
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
